Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus Price Target from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned a consensus rating of “Hold” from the eight brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $3.75.

A number of equities research analysts recently issued reports on the company. HC Wainwright lowered their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Citizens Jmp cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Bank of America lowered their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st.

Werewolf Therapeutics Trading Up 3.4%

NASDAQ:HOWL opened at $0.67 on Friday. Werewolf Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.38. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The firm’s 50 day moving average is $0.77 and its 200 day moving average is $1.21. The stock has a market capitalization of $32.57 million, a PE ratio of -0.41 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Sell-side analysts expect that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Insiders Place Their Bets

In other Werewolf Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total transaction of $171,395.36. Following the completion of the transaction, the insider owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. The trade was a 2.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Luke Evnin sold 108,606 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the completion of the sale, the director directly owned 2,550,674 shares in the company, valued at approximately $1,555,911.14. The trade was a 4.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,289,939 shares of company stock worth $5,345,463 in the last quarter. 23.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth $92,000. Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics in the 3rd quarter valued at about $304,000. Vanguard Group Inc. boosted its position in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares in the last quarter. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.